CAPRISA news release
Young women 15-24 years in sub-Saharan African continue to bear the brunt of the HIV epidemic. Researchers from the Centre for the AIDS Programme of Research in South Africa (CAPRISA) announced the results of a Phase II clinical trial evaluating long-acting broadly neutralising antibodies (bnAbs) for preventing HIV infection in young women at AIDS 2026.
Read the full news release here.
Source : CAPRISA
Related HIV and Co-Infections News
-
[AIDS 2026] MedPage Today: Long-acting lenacapavir still delivered effective HIV PrEP after a year
-
[AIDS 2026] Managed Healthcare Executive: Community-led chemsex harm reduction programs boost HIV retention in South Africa, other countries
-
[AIDS 2026] aidsmap: Promise of monthly oral pill sparks renewed interest in post-exposure prophylaxis (PEP)
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.